In a Comment article published in the scientific journal Nature, Dr. Erica Ollmann Saphire and colleagues outline how a collaborative strategy among researchers can speed up the discovery of treatments for diseases such as Ebola and Zika.
Zalgen Labs LLC (Zalgen), a biotechnology and diagnostics company focused on high-impact, neglected infectious diseases, today announced the launch of a new web-based marketplace to further affirm the Company as the global leader in e-commerce for hemorrhagic fever research and clinical testing.
Abstract - The magnitude of the 2013-2016 Ebola virus disease (EVD) epidemic enabled an unprecedented number of viral mutations to occur over successive human-to-human transmission events, increasing the probability that adaptation to the human host occurred during the outbreak.
He was a globally renowned expert in tropical diseases, and the hero who ran Sierra Leone’s worst Ebola ward. So why, when he finally fell ill, was he denied the extraordinary treatments that could have saved him?
Abstract - Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively.
Background - The 2013-2016 West African Ebola virus disease (EVD) epidemic is the largest recorded. Triage on the basis of clinical signs had limited success, and the time to diagnosis by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) could exceed 5 days.
In two separate articles published in The Journal of Infectious Diseases, VHFC researchers from Nigeria and Sierra Leone provide key insights into the Ebola outbreak response that took place during the 2013-2016 Ebola epidemic.